Interaction aspects of antimycobacterial drugs in the chemotherapy of tuberculosis. I. Role of individual antituberculous drugs in drug regimens used in the chemotherapy of human tuberculosis.
D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003523:Cycloserine / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D013828:Thioacetazone / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D003523:Cycloserine; D013828:Thioacetazone; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin